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A reversed-phase high-performance liquid chromatography (HPLC) and liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method was applied to study the
forced degradation behavior and stability of epidepride. 123I radioisotope-labeled epidepride,
[(-)-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-5-iodo-2,3- dimethoxybenzamide] is a radiotracer
with a high affinity for dopamine D2 receptors in the brain and has been used as an imaging
agent for single-photonemissioncomputed tomography.HPLCstudieswereperformedusing
127I-epidepride (the nonradioactive compound), instead of 123I-epidepride, with an RP-18
column using a mobile phase consisting of methanol, acetonitrile, and ammonium acetate
(pH 7.0, 10mM). The eluent flow rate and thewavelength for HPLC detectionwere 0.5mL/min
and 210 nm, respectively. The ligand was exposed to acid (1 N HCl) and alkaline (1 N NaOH)
media andwas subjected to oxidative decomposition at roomtemperatureusing 3%H2O2 and
to thermal decomposition at 50C. After various reaction times (30minutes, 1 hour, 2 hours, 8
hours, and 24 hours), the substances were investigated by HPLC and LC-MS/MS. Although no
decomposition products were observed after the acidic, alkaline, and thermal treatments,
>80% of the initial amount of 127I-epidepride was oxidized within 24 hours in the presence of
H2O2. Only onemajor oxidation productwith anm/z value of 435was observed, in addition to
the 127I-epidepride species (m/z 419). The product was characterized by LC-MS/MS fragmen-
tation, and the deteriorated type and fragmentation pathwayswere proposed for epidepride.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
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j o u r n a l o f f o o d and d ru g an a l y s i s 2 2 ( 2 0 1 4 ) 2 4 8e2 5 6 2491. Introduction According to the current International Conference onDopamine belongs to a family of neurotransmitters, along
with serotonin, acetylcholine, and norepinephrine, which is
released from the central nervous system (CNS), which in-
cludes the midbrain, substantia, and hypothalamus [1]. In
mammals, dopamine plays an important role in controlling
movement, memory, pleasure, reward, sleep, mood, learning,
behavior, and cognition, among others [2]. An excess or a
deficiency of this vital chemical may lead to various disorders
including Parkinson’s disease and drug addiction [3e5]. Ef-
fects of dopamine occur via dopamine receptors, which
transmit neural signals and regulate many activities. There-
fore, dopamine receptors are the targets of common neuro-
logical drugs. There are five subtypes of dopamine receptors
that are present at higher levels: D1, D2, D3, D4, and D5 [6], but
D1 and D2 are the major subtypes, accounting for >90% of all
the dopamine receptors. The D2 dopamine receptor serves as
an information transmitter and neurotransmission regulator;
hence, the development of a new D2 receptor antagonist drug
for the treatment and/or diagnosis of CNS disorders is
important.
Epidepride, (S)-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-
iodo-2,3-dimethoxybenzamide (Fig. 1), is one of the mem-
bers of a family of compounds with a high affinity for the
dopamine D2 receptor antagonist [7]. Radioisotopes of iodine
(123/125I), which emit g radiation, have been used to substituted
127I in epidepride, leading to 123/125I-epidepride; a compound
that was first developed by Kessler et al [8] in 1991, to study
precisely the activity and distribution of the D2 receptor in the
brain during Parkinson’s disease, by single photon emission
computed tomography (SPECT) [9]. Epidepride was originally
derived from the structures of (S)-sulpiride and remoxipride.
123I-epidepride is better than 123iodobenzamide, which is
another D2-receptor imaging-agent candidate with high
specificity and affinity [10,11]. de Herder et al [10] have re-
ported that 123I-epidepride scans allow a consistently superior
visualization of pituitary adenoma, and suggested that this
compound could potentially replace 123I-iodobenzamide in
future studies of D2-receptors by SPECT. Leslie et al [11] and
Huang et al [5] also showed that 123I-epidepride is a promising
radiotracer for evaluating the therapeutic effects of schizo-
phrenia. Pirker et al [12] reported a high sensitivity (in the
picomole range) of 123I-epidepride-based SPECT, which can be
applied to predict the effects of dopamine treatment on pi-
tuitary tumors.CH3CH3
O
I
CH3
O
O
NH
N
Fig. 1 e Structure of 127I-epidepride, C16H23N2O3I e
(molecular weight [ 418.3).Harmonization (ICH) “Stability Testing Guidelines”, a new
drug should undergo a series of analytical tests, and the as-
says should be fully validated. Moreover, the guidelines sug-
gest that the drug should be subjected to stress testing or
forced degradation studies [13]. Stress testing of a drug is used
to survey the stability of a given system or an entity. It in-
volves testing the substance beyond normal operational con-
ditions. By contrast, a stability indicatingmethod is defined as
a part of validated analytical methods that can accurately and
precisely quantitate the decrease in active pharmaceutical
ingredients due to degradation [14]. Therefore, it is important
to be able to identify the possible degradation products, which
is in turn helpful for determining the degradation pathways
and the intrinsic stability of the molecule and for validating
the stability e indicating the power of the drug during
analytical procedures. According to the guidelines, the test
should also include the effects of temperature, humidity
(where appropriate), oxidation, photolysis, and susceptibility
to hydrolysis across a wide pH range. Stability testing aims to
evaluate the quality of a drug, determine whether the product
changes with time under various environmental factors, and
establish a retesting period for the substance or recommend a
shelf life and appropriate storage conditions for the drug [15].
Information about the degradation pathways and the degra-
dation products that can possibly form during storage or
manufacturing processes may improve pharmaceutical
safety, in which a better control of the chemical behavior of a
drug could help maintain its quality [16].
This study established high-performance liquid chroma-
tography (HPLC) and liquid chromatographyetandem mass
spectrometry (LC-MS/MS) methods to monitor the rate and
identify the structure of the degradation products formed
during stress-testing studies of epidepride. We studied the
inherent stability of the compound through stress studies
carried out under different conditions, including thermal,
acidic/alkaline hydrolysis, and oxidative to determine the
stability and ensure the quality of this chemical compound,
which serves as an active pharmaceutical ingredient. To
follow the regulatory requirements for radiation safety pro-
grams (“As Low As Reasonably Achievable”, ALARA), 127I-epi-
depride was used instead of 123I or 125I-labeled epidepride in
the study.2. Materials and methods
2.1. Materials and reagents
Analytical-grade laboratory chemicals for HPLC were used as
received without further purification. Methanol, acetonitrile
(both HPLC grade), ammonium acetate, sodium hydroxide,
hydrochloric acid and H2O2 (30%) were all purchased from
Merck (Darmstadt, Germany). Deionized water was purified
using a Smart DQ3 reverse osmosis reagent water system
(Merck Millipore, Billerica, MA, USA) with a 0.22-mmfilter, total
organic carbon (TOC) <5 ppb, resistivity 18 MU cm, and
endotoxin 0.001 EU/mL. 127I-epidepride was synthesized and
purified, following the procedures briefly described in the next
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Fig. 2 e Scheme for the preparation of epidepride.
Table 1 e Tandem mass spectrometry parameters for
epidepride determination.
Parameters Epidepride
Source temperature (C) 500
Polarity Positive
Resolution, Q1 and Q3 Unit
Nebulizer gas, NEB (psi) 45
Curtain gas, CUR (psi) 10
Turbo gas 50
Collision gas, CAD (psi) Medium
Ion spray voltage, IS (V) 5500
Ion energy 1, IE1 (V) 0.6
Ion energy 3, IE3 (V) 0.2
Declustering potential, DP (V) 100
Entrance potential, EP (V) 10
Detector parameter Positive
－Channel electron multiplier, CEM (V) 1950
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Research (INER; Longtan Township, Taoyuan County, Taiwan,
R.O.C.). Reagent-grade laboratory chemicals for the synthesis
were obtained from commercial sources. 5-Iodo-2,3-
dimethoxy benzoic acid, thionyl chloride, bis(triphenyl-
phosphine)-palladium(II) chloride, and (S)-(-)-2-aminomethyl-
1-ethylpyrrolidine were purchased from Merck. Infrared
spectra were obtained on a Bio-Rad FTS-40 spectrometer (Bio-
Rad Co., Hercules, CA, USA). 1H and 13C nuclear magnetic
resonance (NMR) spectra were recorded on a Varian Gemini
2000 spectrometer (300 MHz) (Varian Inc., Palo Alto, CA, USA).
Gas chromatography was performed on a Shimadzu GCMS-
QP 1100EX (Shimadzu Co., Kyoto, Japan).
2.2. Synthesis procedures and spectra of 127I-epidepride
A solution of 5-iodo-2,3-dimethoxybenzoic acid (1.0 g,
3.2 mmol) in thionyl chloride (10 mL) was heated under reflux
for 2 hours, and concentrated under reduced pressure. The
residue was redissolved in dichloromethane (20 mL), and the
solution was cooled to around 4C. (S)-(-)-2-Aminomethyl-1-
ethylpyrrolidine (0.41 g, 3.2 mmol) in dichloromethane
(10 mL) was added dropwise, and the resultant solution was
stirred for 3 hours at room temperature, washed thoroughly
with 1 N NaOH (20 mL), dried over anhydrous Na2SO4,
concentrated, and finally purified by chromatography (SiO2,
dichloromethane/methane ¼ 19:1) to yield epidepride (1.27 g,
95%). The synthesis reaction scheme is shown in Fig. 2 [17,18].
Spectra of epidepride: IR (neat) n 3376 (NH), 1659 (C]O)
cm1; 1H NMR (CDCl3) d 8.32 (br, 1 H, NH), 8.03 (d, J ¼ 2.1 Hz, 1
H, Ph-H), 7.29 (d, J ¼ 2.1 Hz, 1 H, Ph-H), 3.89 (s, 3 H, OCH3), 3.88
(s, 3 H, OCH3), 3.76 (ddd, J ¼ 13.8, 7.2, and 2.4 Hz, 1 H, NHCH2),
3.30 (ddd, J ¼ 13.8, 5.1, and 2.7 Hz, 1 H, NHCH2), 3.19 (m, 1 H,
NCH2CH2), 2.86 (m, 1 H, NCH2CH3), 2.64 (m, 1 H, NCH), 2.21 (m,
2 H, CH2CH3 and NCH2CH2), 1.88 (m, 1 H, CHCH2), 1.69 (m, 3H,
NCH2CH2CH2), 1.12 (t, J ¼ 7.2 Hz, 3 H, CH2CH3); 13C NMR (CDCl3)
d 163.76 (CO), 153.15, 147.56, 131.64, 128.27, 123.85, and 87.09
(Ph), 62.11 (CH), 61.19 (OCH3), 56.24 (OCH3), 53.35, 47.71, 40.92,
28.20, and 22.50 (CH2), 13.86(CH3); GC-MS m/z 418 (M
þ), 403
(Mþ-CH3), 389 (M
þ-CH2CH3), 320 (M
þ-CH(CH2)3NCH2 CH3), 291
(Mþ-NHCH2CH(CH2)3NCH2CH3).
2.3. Apparatus and equipment
2.3.1. HPLC instrumentation
Quantification and studies of the degradation behavior of
epidepride were performed on an Agilent 1100 series HPLC
system (Agilent, Palo Alto, CA, USA), which consisted of an on-
line degasser, a binary pump, an autosampler, a thermostated
column oven, and a photodiode array detector (PDA). The datawere acquired and processed using Agilent ChemStation
software (Agilent), and a porous monolithic silica (with
bimodal pore structure, i.e., macropores with 2 mm and mes-
opores 13 nm in diameter) surface modified with octade-
cylsilan and full end-caping reversed-phase column,
according to the manufacturer instructions (Chromolith Per-
formance RP-18e, 4.6 100mm,Merck, Darmstadt, Germany),
was used for LC separation. The column temperature was
maintained at 25C. Isocratic elution was achieved using a
mobile phase consisting of methanol and acetonitrile (15:85,
v/v) added with ammonium acetate (pH 7.0, 10 mM) as buffer.
The flow rate was 0.5 mL/min, and the injection volume was
5 mL. The optimal wavelength for the detection and quantifi-
cation of the drug and its degradation products was set at
210 nm.
2.3.2. LC-MS/MS instrumentation
Mass spectrometric analysis was carried out on a 4000 QTrap
LC-MS/MS system, containing the API Analyst software 1.4.1
(MDS Sciex, Vaughan, Ontario, Canada), to study the frag-
mentation ions and the forced degradation product of epi-
depride. The samples were introduced into the spectrometer
either by the HPLC system (Agilent 1100) or by a syringe pump
at a flow rate of 10 mL/min (Harvard, Harvard Apparatus,
Holliston, MA, USA). Chromatographic separation was con-
ducted as described in the section on HPLC conditions. The
analytes were ionized by a turbo spray ion source (electro-
spray ionization) in the positive-ionmode at 5500 V and 500C.
Mass spectra were recorded within the range of 50e1000 amu
with unit resolutions in Q1 and Q3. Other experimental pa-
rameters are outlined in Table 1. Determination of the epi-
depride concentration by LC-MS was conducted in the
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Fig. 3 e High-performance liquid chromatography of epidepride.
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trogen was used as the nebulization, curtain, and collision gas
in all the 4000 QTrap LCeMS/MS studies.
2.3.3. Other equipment
A pH meter (Sartorius AG, Goettingen, Germany) was used to
check and adjust the pH of the buffer solutions. Temperature
accuracy and constancy of the oven (Binder GmbH, Tut-
tlingen, Germany) were previously calibrated and then used
for the subsequent thermal-stress study.2.4. Procedures
To verify that the HPLC analytical method was suitable to
determine epidepride, including linearity, precision, and ac-
curacy were determined according to the guidelines: “ICH
Topic Q 2 (R1): Validation of analytical procedures: text and
methodology” issued by the European Medicines Agency [16].
2.4.1. Linearity
To establish analytical calibration linearity and the appro-
priate range for the epidepride studies by HPLC, a stock solu-
tion containing 1000 mg/mL drug in methanol was prepared.
This stock solution was then diluted to yield analyte solutionsTable 2 e Data of intra-day and inter-day precision
studies (n[ 3).
Concentration
(mg/mL)
Intra-day measured
concentration (mg/
mL)  SD; RSD%
(n ¼ 3)
Inter-day measured
concentration (mg/
mL)  SD; RSD%
(n ¼ 3)
10 10.450  0.124; 1.182 10.662  0.212; 1.990
50 49.078  0.158; 0.322 48.541  0.145; 0.298
75 77.909  1.325; 1.701 77.956  1.391; 1.784
RSD ¼ relative standard deviation; SD ¼ standard deviation.in the concentration range of 1e100 mg/mL, which were
freshly prepared daily. The solutions were injected in tripli-
cate into the HPLC system, and the calibration curve was then
obtained by plotting the respective peak areas against the
concentrations. Quality control samples of 10 mg/mL, 50 mg/
mL, and 75 mg/mL were similarly prepared. Linearity was
evaluated by the linear least-square regression method. The
calibration curves for epidepride through MRM positive-ion
detection mode using LC-MS/MS were also established be-
tween the concentration range of 1e100 ng/mL.
2.4.2. Precision
Intra-day precision was established by analyzing 10 mg/mL,
50 mg/mL, and 75 mg/mL epidepride solutions in triplicate on
the same day and calculating the values of the relative stan-
dard deviation (RSD). The studies were also repeated on
different days to determine inter-day precision.
2.4.3. Accuracy
The accuracy was assayed by the recovery test. Samples were
spiked with three known amounts of epidepride (10 mg/mL,
50 mg/mL, and 75 mg/mL) in triplicate, and then the percentage
recovery of the added drug was determined.
2.4.4. Stress studies
Stress studies of epidepride were carried out under different
conditions including acidic and alkaline hydrolysis,Table 3 e Recovery studies.
Concentration
(mg/mL)
Calculated concentration
(mg/mL)  SD; RSD% (n ¼ 3)
Recovery (%)
10 9.76  0.16; 1.681 97.6
50 48.97  0.38; 0.768 97.9
75 76.20  0.98; 1.291 101.6
RSD ¼ relative standard deviation; SD ¼ standard deviation.
 +MS2 (419.50) CE (30): 0.014 to 0.268 min from Sample 1 (0.2 ppm Epidepride MS2 of 419.5 01) of 20090618 Epidepride MS2 scan.wiff (Turbo ... Max. 3.6e4 cps.
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Fig. 4 e Mass spectra of epidepride: (A) Q1 full scan, (B) tandem mass spectrometry from m/z 419.
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dissolved in 0.33 mL methanol (3 mg/mL) and immersed in
0.33 mL 1 M HCl or 1 M NaOH at ambient temperature for 30
minutes, 1 hour, 2 hours, 8 hours, and 24 hours. The acidic
and alkaline hydrolysis samples were neutralized using
0.33 mL 1 M NaOH or 1 M HCl, respectively, prior to HPLC
analysis. The oxidation study was performed by mixing
0.5 mL of 2 mg/mL epidepride solution with 0.5 mL 3% H2O2
and maintaining the mixture at room temperature for 30
minutes, 1 hour, 2 hours, 8 hours, and 24 hours. For the
thermal stress studies, about 1 mg of the drug was sealed in
glass vials and placed in an oven at 50C for the same times
mentioned above [19,20]. After incubation the samples were
diluted into 10 times volume in methanol for HPLCePDA
analysis.3. Results and discussion
3.1. HPLC method development
A reversed-phase HPLC method was developed to study epi-
depride. The ligandwas analyzed on amonolithic silica with a
characteristic porous structure, whereas surface modified
with C-18 and a fully end-caping column using a 15:85
methanoleacetonitrile mixture, and ammonium acetate
(10 mM, pH 7.0) was added to both solvents. The absorption
spectra of epidepride were recorded between 200 nm and
300 nm using a post-column PDA. The detection wavelength
was set at 210 nm for determination of epidepride (including
decomposed products). A typical HPLC chromatogram
Table 4 e Optimized mass spectrometry parameters for linearity studies of the MRM transitions of 127I-epidepride.a
MRM transitions DP EP CE CXP Linear regression eq. Corr. coeff. (r2)
419.4/291.4 100 10 41 15 y ¼ 5.70  103x e 4.35  103 0.9970
419.4/276.3 55 16 y ¼ 193  x e 168 0.9987
419.4/248.5 60 14 y ¼ 1.94  103x e 2.60  103 0.9991
419.4/112.5 35 4 y ¼ 3.94  103x e 4.24  103 0.9992
419.4/98.4 55 6 y ¼ 2.25  103x e 2.01  103 0.9993
419.4/84.3 70 2 y ¼ 356  x e 233 0.9993
419.4/58.4 65 2 y ¼ 768  x e 583 0.9995
CE ¼ collision energy; Corr. coeff. ¼ correlation coefficient; CXP ¼ collision cell exit potential; DP ¼ declustering potential; EP ¼ entrance po-
tential; eq. ¼ equation; MRM ¼ multiple reaction monitoring.
a Dynamic range: 1e100 ng/mL.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 2 ( 2 0 1 4 ) 2 4 8e2 5 6 253obtained for epidepride is shown in Fig. 3 [retention
time ¼ (2.37  0.01) minutes, RSD ¼ 0.44%, n ¼ 18].
3.2. Linearity
With the HPLC method described above, the calibration curve
(with six concentration points) for epidepride was sufficiently
linear in the concentration range between 1 mg/mL and 100 mg/
mL. The linear least-square regression equation was
y ¼ 20.26 c 22.54, with a correlation coefficient (r2) of 0.999.CH3CH3
O
I
CH3
O
O
NH2
+
N
CH3
O
CH3
O
O
NHC+
CH
CH2
+
CH3
CH +
N
CH3
CH
CH3
O
CH3
O
O
C+
m/z 419.3
m/z 165.1
CH3
NH
CH2
+
m/z 58.1
-HI
-128
[MH]+
-
-26
-126
Fig. 5 e Proposed fragmentatioThe limit of detection and limit of quantification for the ligand
were 0.02 mg/mL and 0.1 mg/mL, respectively.
3.3. Precision
The data for the intra- and inter-day precision studies, carried
out within the linearity range at three different concentra-
tions (10 mg/mL, 50 mg/mL, and 75 mg/mL), are shown in Table 2.
The RSD values for the intra-day and inter-day precision study
were <2%, which confirmed that the method was precise.CH3
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The percentage recovery was calculated by interpolating the
peak areas of the spiked samples to the linear regression
equation of the calibration curve. As shown in Table 3, good
recoveries were obtained (95e105%), indicating that the
developed method was sufficiently accurate. The validation
results of the developed HPLC method regarding linearity,
precision, and accuracy for epidepride measurements con-
formed well with the criteria listed in the guidelines issued by
the ICH [16].3.5. MS analysis of epidepride
MS analyses of epidepride fragments were initially performed
by syringe infusion to introduce the sample solution into the
equipment for Q1 and MS/MS scans. Full Q1 spectra were
achieved in the negative-ion and positive-ion modes, but the
latter mode was preferred because it gave more structural
information about epidepride. In the electrospray ionization0 2 4
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Fig. 7 e High-performance liquid chromatography of epidepride
DP [ degenerated product.spectra of epidepride, [M þ H]þ ions were observed at an m/z
value of 419.3 (Fig. 4A). Product-ion scans were carried out at
different collision-activated dissociation conditions to opti-
mize the declustering potential (DP), entrance potential,
collision energy, and collision cell exit potential. The product-
ions of 419 were observed at m/z value of 291.4, 276.3, 248.5,
112.5, 98.3, 84.5, and 58.4 (Fig. 4B). LC-MS MRM transitions
were also studied and are given, together with the optimized
MS parameters, in Table 4, where the linear least-square
regression equations and the correlation coefficients are also
listed. The drug response was strictly linear, with all the
investigated MRM transitions over the calibration range
(r2  0.998). The best quantification equation for the MRM
transition was 419/112, with a highly sensitive slope and
linearity across the concentration range between 1 ng/mL and
100 ng/mL. The limit of detection and limit of quantification
for epidepride using MRM (419/112) were 0.01 ng/mL and
0.05 ng/mL, respectively. The others MRM pairs were used as
criteria for identification in complicated-matrix specimen.
Based on the performance of the established LC-MS/MS MRM
method, we will investigate the bio-distribution (Bio-D) issue
of epidepride from animal experiments in the future after the
bioanalytical method is validated.
MS/MS fragmentation ions and a fragmentation pathway
of epidepride are proposed on the basis of the MS/MS spectra
in Fig. 5. The CeI bond could be easily cracked, because iodide
is a good leaving group. The methyl groups of methoxybenzyl
in the structure of epidepride were the second most easily
cracked bonds, because the oxygen radicals are delocalized
around the benzene ring.3.6. Degradation behavior
Primarily, no epidepride degradation products were observed
under acidic/alkaline hydrolysis and thermal decomposition
conditions, although the retention time of the parent drugmin6 8
me (min)
after being subjected to oxidative conditions for 24 hours.
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Fig. 8 e Product-ion spectrum of DP#1 with m/z 435 and its possible structure. DP [ degenerated product.
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solutions. The ligand was relatively stable under such harsh
conditions, and the trends of the forced degradation studies
are plotted in Fig. 6. The chromatographic purities of epi-
depride, obtained fromHPLC studies after acidic, alkaline, and
thermal stress testing of the sample, were >97.5%, despite
incubation for 24 hours. However, >80% of the original
amount of epidepride deteriorated within 24 hours under
oxidative conditions, and a degenerated product peak (DP#1,
tR 3.13 min) appeared and the peak area increased gradually
after the beginning of the reaction for 30 minutes. A chro-
matogram of the oxidation product, obtained after 24 hours, is
shown in Fig. 7. The m/z value of epidepride is 419, but we
found (through a Q1 scan by LCeMS) that the degenerated
epidepride product DP#1 had anm/z value of 435. The tandem
mass spectrum of product-ions from the m/z 435 is shown in
Fig. 8, and all the product-ions observed in this spectrum also
existed as fragments of epidepride. It could thus be demon-
strated that DP#1 originated from epidepride; therefore, we
believe that DP#1 should be an oxidation product of epi-
depride. A possible structure for DP#1 is illustrated in Fig. 8,
which shows that iodo-phenyl is oxidized into hydroxy-iodo-
phenyl, instead of the core structure of epidepride being
oxidized, so that does not shift the m/z values of fragments
from epidepride. The proposed structure of DP#1 originates
from the character of iodine with multi-oxidation-state
bonding. The results also suggest that iodo-phenyl bonding
is an active site to undergo various reactions.4. Conclusions
HPLC and LCeMS/MS methods for epidepride determination
were developed and verified. A series of stress studies was
conducted on the ligand based on the HPLC and LCeMS
analysis method, showing that epidepride is stable under
thermal, acidic, and alkaline hydrolysis conditions butdeteriorates easily in an oxidative medium. The fragmenta-
tion pathways of epidepride and a possible oxidized structure
were also proposed, and the iodide bond could be cracked and
oxidized easily. The results of this study suggest that the drug
should be stable within a wide pH range under ambient
temperature conditions (with a long shelf life), but must be
protected from oxidizing agents, and it may become a
hydroxyl-iodo compound. Understanding the fragmentation
pathways of epidepride could also help us to determine
possible metabolites structures from LCeMS/MS studies on
animal models in the future.r e f e r e n c e s
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